Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04903951

Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever Stroke

To evaluate the impact of early ventilation in stroke outcomes in patients with sleep apnea and first ever stroke, 1 month after stroke.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Unidade Local de Saúde de Matosinhos

Matosinhos Municipality, Portugal

Location status: Recruiting

Location contact

Sílvia Correia, MD

CONTACT

About this study

Single-center, randomized, open label, parallel arm, prospective study in patients with sleep apnea after first-ever stroke.

The study will consist of screening, baseline assessment, interventional period (consisting of a treatment period and follow-up visits), and a follow-up phone call.

Patients will be randomly assigned to ASV (active) or control groups, within 4 days after the PSG II and will start the respective intervention in the same day.

Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated. Patients assigned to control group will receive best medical treatment for stroke alone, including rehabilitation.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent obtained from the participant or the legally acceptable representative, prior to any study-related procedure.
  • Male or female between 18 and 80 years, inclusive, at the time of signing the informed consent.
  • Admission to the hospital within 48 h of stroke symptoms onset.
  • Ischemic first stroke diagnosis.
  • NIHSS ≥2 at screening.
  • Sleep apnea with AHI ≥15.

Exclusion criteria

  • CSA with Left Ventricular Ejection Fraction ⩽45%.
  • Ventilation treatment for sleep apnea diagnosis, prior to stroke.
  • Risk of aspiration.
  • Nasogastric feeding tube.
  • Transient ischemic attack, hemorrhagic stroke or subarachnoid hemorrhage.
  • Stroke due to a secondary cause (e.g. vascular malformation, vasculitis, brain tumor, head trauma, or predisposition to bleeding).
  • Cardiorespiratory distress.
  • Advanced chronic lung disease requiring supplemental oxygen.
  • Concomitant central nervous system diseases such as dementia or multiple sclerosis.
  • Uncontrolled psychosis or agitation.
  • Glasgow Coma Scale (GCS) score <10 at screening.
  • Anosognosia, global or Wernicke aphasia.
  • Insufficient upper limbs function to use a mask and no overnight caregiver to help.
  • Inability to attend to the rehabilitation program of the hospital.
  • Pregnant and breast-feeding women.
  • Participation in another clinical study (except a standard-of-care registry).
  • Any other condition that, according to the Investigator, renders the subject unsuitable for ventilation.

Treatment and study plan

Adaptive Servoventilation (ASV) therapy

Device

Patients assigned to the active group will receive ventilatory support with ASV (DreamStation BiPAP autoSV®) during diurnal and nocturnal sleep, from study randomization until clinically indicated

Best Medical Treatment

Other

Best medical treatment for stroke, including rehabilitation

Primary outcomes

  1. Proportion of patients with improvement in neurological parameters (reduction of ≥1 point from the beginning in Rankin scale) 1 month after stroke.

    Time frame: 1 month after stroke

Secondary outcomes

  1. Proportion of patients with improvement in neurological parameters (reduction of ≥1 point from the beginning in Rankin scale) at 4 and 6 months after stroke.

    Time frame: 4 and 6 months after stroke

  2. Change from baseline in National Institutes of Health Stroke Scale (NIHSS) to measure improvement in neurological parameters at month 1, 4 and 6 after stroke.

    Time frame: 1, 4 and 6 months after stroke

  3. Type II full polysomnography (PSG II) within 7 days of stroke symptoms onset in all patients with AHI >5 as assessed by ApneaLink™

    Time frame: Within 7 days after admission

  4. Adherence in the Servoventilation group

    Time frame: After 1, 4 and 6 months

    % nights of device use; average hours per night of device use

  5. Efficacy in the Servoventilation group

    Time frame: After 1, 4 and 6 months

    Apnea-Hypopnea Index

  6. Adverse events monitoring

    Time frame: Through study completion, an average of 2 years

    All AEs occurring within the period of observation for the clinical study must be fully evaluated, documented, reported (if applicable) and archived.

  7. Cardiovascular events evaluation at month 1, 4 and 6 months after stroke in randomized patients

    Time frame: 1, 4 and 6 months after stroke

  8. Cardiovascular events evaluation 12 months after stroke in all participants.

    Time frame: 12 months after stroke

Study contacts

Contact information is provided by the study sponsor or research team.

Sílvia Correia, MD

CONTACT

[email protected]

00351969043466

Sponsors and collaborators

Lead sponsor

Philips Portuguesa S.A.

Industry

Registry information

Official study title

A Single-center, Randomized, Open Label, Parallel Arm, Prospective Study to Evaluate the Impact of Early Ventilation in Stroke Outcomes in Patients With Sleep Apnea After First Ever Stroke

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 27, 2021
Registry last updated
Aug 12, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.